Company: LIMN
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001104659-25-111651
Chunk: 1

Company: Liminatus Pharma, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1F
Chunk 1
---
Item 1. Financial Statements.

Liminatus Pharma, Inc.

Condensed Consolidated Balance Sheets

​

​​​​​​​​    September 30,     December 31, ​​2025​2024ASSETS​(Unaudited)​​​Current assets ​   ​  Cash​$ 724,502​$ 56,319Loan receivable​​ —​​ 3,668,500Deferred transaction costs​​ —​​ 1,401,323Prepaid and other current assets​​ 478,868​​ 155,501Total current assets​​ 1,203,370​​ 5,281,643Non-current assets:​​​​​​Due from related party, non-current​​ 126,275​​ 126,275Property and equipment, net​​ 12,764​​ 941Total non-current assets​​ 139,039​​ 127,216Total assets​$ 1,342,409​$ 5,408,859​​​​​​​LIABILITIES AND STOCKHOLDERS’ DEFICIT​​​​   Current liabilities​​​​   Accounts payable and accrued expenses​$ 559,171​$ 1,483,253Accrued interest, related parties​​ 184,869​​ 955,119Accrued maintenance fee​​ —​​ 360,000Due to research and development partner​​ —​​ 1,782,297Due to related parties​​ 178,053​​ 195,253Short-term debt, related parties​​ 1,442,500​​ 19,973,000Deferred underwriting fee payable​​ 500,000​​ —Total current liabilities​​ 2,864,593​​ 24,748,922Warrant liability​  123,579​  —Total liabilities​​ 2,988,172​​ 24,748,922​​​​​​​Commitments and Contingencies (Note 7)​   ​   ​​​​​​​Stockholders’ deficit​   ​   Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding*​​ —​​ —Common stock, $0.0001 par value; 500,000,000 shares authorized; 27,064,633 and 17,500,000 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively*​  2,706​